AC Immune (ACIU) News Today $1.75 +0.01 (+0.57%) Closing price 05/20/2025 04:00 PM EasternExtended Trading$1.84 +0.09 (+4.86%) As of 08:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACIU Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period AC Immune SA Announces Board Changes Ahead of June 2025 AGMMay 19 at 7:24 AM | tipranks.comAC Immune (NASDAQ:ACIU) Upgraded to Buy at StockNews.comStockNews.com upgraded AC Immune from a "hold" rating to a "buy" rating in a research report on Tuesday.May 15, 2025 | marketbeat.comAC Immune (ACIU) Expected to Announce Earnings on MondayMay 11, 2025 | americanbankingnews.comAC Immune (ACIU) to Release Earnings on MondayAC Immune (NASDAQ:ACIU) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-ac-immune-sa-stock/)May 7, 2025 | marketbeat.comEquities Analysts Issue Forecasts for AC Immune Q2 EarningsAC Immune SA (NASDAQ:ACIU - Free Report) - HC Wainwright boosted their Q2 2025 earnings estimates for shares of AC Immune in a research report issued to clients and investors on Thursday, May 1st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.21)May 6, 2025 | marketbeat.comFY2027 EPS Estimates for AC Immune Reduced by HC WainwrightAC Immune SA (NASDAQ:ACIU - Free Report) - Research analysts at HC Wainwright reduced their FY2027 EPS estimates for shares of AC Immune in a report issued on Thursday, May 1st. HC Wainwright analyst A. Fein now forecasts that the company will earn $0.12 per share for the year, down from their prMay 4, 2025 | marketbeat.comAC Immune SA Reports Q1 2025 Financial Results and Clinical Advancements in Neurodegenerative Disease TherapiesMay 1, 2025 | nasdaq.comAC Immune SA: AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 1, 2025 | finanznachrichten.deAC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateApril 30, 2025 | globenewswire.comIndividual investors in AC Immune SA (NASDAQ:ACIU) are its biggest bettors, and their bets paid off as stock gained 11% last weekApril 26, 2025 | finance.yahoo.comQ2 Earnings Forecast for AC Immune Issued By Leerink PartnrsAC Immune SA (NASDAQ:ACIU - Free Report) - Investment analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for AC Immune in a research note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn ($0.17) per shaApril 18, 2025 | marketbeat.comQ1 Earnings Forecast for AC Immune Issued By Leerink PartnrsAC Immune SA (NASDAQ:ACIU - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for AC Immune in a research note issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman forecasts that the company will earn ($0.22) per share for the quarter. The consensus eApril 17, 2025 | marketbeat.comAC Immune (NASDAQ:ACIU) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of AC Immune in a research note on Thursday.April 5, 2025 | marketbeat.comAC Immune SA: Promising Phase 2 Results and Positive Outlook Drive Buy RatingApril 4, 2025 | tipranks.comAC Immune’s Strategic Advances and Financial HighlightsApril 3, 2025 | tipranks.comAC Immune announces additional data from Phase 2 study of VacSYn clinical trialApril 2, 2025 | markets.businessinsider.comAC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseApril 2, 2025 | markets.businessinsider.comAC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's DiseaseApril 2, 2025 | globenewswire.comShort Interest in AC Immune SA (NASDAQ:ACIU) Rises By 23.9%AC Immune SA (NASDAQ:ACIU - Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 1,350,000 shares, an increase of 23.9% from the February 28th total of 1,090,000 shares. Currently, 2.2% of the company's stock are short sold. Based on an average daily volume of 182,400 shares, the days-to-cover ratio is presently 7.4 days.April 1, 2025 | marketbeat.comAC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025March 25, 2025 | globenewswire.comPromising Developments in AC Immune SA’s ACI-7104 Program Drive Buy RatingMarch 18, 2025 | tipranks.comAC Immune: Promising Pipeline and Financial Stability Drive Buy RatingMarch 17, 2025 | tipranks.comAC Immune (NASDAQ:ACIU) investors are sitting on a loss of 52% if they invested five years agoMarch 16, 2025 | finance.yahoo.comAC Immune (NASDAQ:ACIU) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $16.00 price target on shares of AC Immune in a report on Friday.March 15, 2025 | marketbeat.comAC Immune (NASDAQ:ACIU) Releases Earnings Results, Beats Estimates By $0.03 EPSAC Immune (NASDAQ:ACIU - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.03.March 14, 2025 | marketbeat.comAC Immune reports FY24 EPS (51c), consensus (54c)March 13, 2025 | markets.businessinsider.comAC Immune Reports Full Year 2024 Financial Results and Provides a Corporate UpdateMarch 13, 2025 | globenewswire.comAC Immune (ACIU) Projected to Post Quarterly Earnings on ThursdayAC Immune (NASDAQ:ACIU) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comAC Immune (NASDAQ:ACIU) Share Price Crosses Below 50-Day Moving Average - Should You Sell?AC Immune (NASDAQ:ACIU) Stock Passes Below 50-Day Moving Average - Should You Sell?March 5, 2025 | marketbeat.comAC Immune to Participate in Upcoming Investor ConferencesMarch 4, 2025 | markets.businessinsider.comAC Immune (NASDAQ:ACIU) Stock Price Passes Below 50 Day Moving Average - Should You Sell?AC Immune (NASDAQ:ACIU) Stock Price Crosses Below 50 Day Moving Average - What's Next?February 23, 2025 | marketbeat.comAC Immune: Leader In Dementia Therapies, A Space Littered With FailuresFebruary 20, 2025 | seekingalpha.comAC Immune FY2024 EPS Forecast Increased by Leerink PartnrsAC Immune SA (NASDAQ:ACIU - Free Report) - Stock analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for AC Immune in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($0.57) per share for the year, up frJanuary 31, 2025 | marketbeat.comAC Immune (NASDAQ:ACIU) Stock Passes Below Fifty Day Moving Average - Here's What HappenedAC Immune (NASDAQ:ACIU) Stock Price Passes Below Fifty Day Moving Average - Here's What HappenedJanuary 17, 2025 | marketbeat.comAC Immune (NASDAQ:ACIU) Shares Down 4.4% - Here's What HappenedAC Immune (NASDAQ:ACIU) Shares Down 4.4% - What's Next?January 9, 2025 | marketbeat.comAC Immune (NASDAQ:ACIU) Stock Passes Below 200-Day Moving Average - Here's What HappenedAC Immune (NASDAQ:ACIU) Share Price Passes Below 200 Day Moving Average - Time to Sell?December 18, 2024 | marketbeat.comAC Immune Announces Promising Safety Data for Down Syndrome TherapyDecember 11, 2024 | markets.businessinsider.comAC Immune Reports Encouraging Interim Safety Data From ABATE Study Of ACI-24.060 In Down SyndromeDecember 10, 2024 | markets.businessinsider.comAC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndromeDecember 10, 2024 | markets.businessinsider.comAC Immune Q3 2024: Strong Progress and Financial TurnaroundNovember 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), Bluebird Bio (BLUE) and AC Immune SA (ACIU)November 19, 2024 | markets.businessinsider.comAC Immune SA: Promising Vaccine Developments and Strategic Partnerships Drive Buy RatingNovember 18, 2024 | markets.businessinsider.comPromising Interim Data and Safety Profile Justify Buy Rating for AC Immune’s ACI-7104.056 Vaccine TrialNovember 16, 2024 | markets.businessinsider.comAC Immune reports interim results from Phase 2 trial of ACI-7104.056November 15, 2024 | markets.businessinsider.comAC Immune’s Promising Trial Results for Parkinson’s TherapyNovember 15, 2024 | markets.businessinsider.comAC Immune SA (NASDAQ:ACIU) Short Interest Up 23.5% in OctoberAC Immune SA (NASDAQ:ACIU - Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 984,500 shares, a growth of 23.5% from the October 15th total of 796,900 shares. Based on an average daily volume of 92,100 shares, the short-interest ratio is currently 10.7 days. Approximately 1.6% of the shares of the stock are sold short.November 15, 2024 | marketbeat.comAC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's PatientsNovember 14, 2024 | benzinga.comAC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseNovember 14, 2024 | markets.businessinsider.comAC Immune to Present at the Jefferies 2024 London Healthcare ConferenceNovember 14, 2024 | markets.businessinsider.comAC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New EstimatesNovember 9, 2024 | finance.yahoo.com Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address ACIU Media Mentions By Week ACIU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACIU News Sentiment▼1.230.65▲Average Medical News Sentiment ACIU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACIU Articles This Week▼21▲ACIU Articles Average Week Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immunome News Today Rocket Pharmaceuticals News Today ArriVent BioPharma News Today Day One Biopharmaceuticals News Today Trevi Therapeutics News Today Immatics News Today Vir Biotechnology News Today Sionna Therapeutics News Today Evolus News Today Replimune Group News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACIU) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
